Does the media refer more to PRQR or CADL?

In the previous week, Candel Therapeutics had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 4 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.79 beat Candel Therapeutics' score of 0.63 indicating that ProQR Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Candel Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to PRQR or SLDB?

In the previous week, Solid Biosciences had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 4 mentions for ProQR Therapeutics. Solid Biosciences' average media sentiment score of 0.92 beat ProQR Therapeutics' score of 0.79 indicating that Solid Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 3 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is PRQR or GERN more profitable?

Geron has a net margin of -34.17% compared to ProQR Therapeutics' net margin of -223.51%. Geron's return on equity of -24.48% beat ProQR Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ProQR Therapeutics -223.51% -73.83% -35.14% Geron -34.17% -24.48% -10.30%

Does the media prefer PRQR or GERN?

In the previous week, Geron had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Geron and 4 mentions for ProQR Therapeutics. Geron's average media sentiment score of 1.76 beat ProQR Therapeutics' score of 0.79 indicating that Geron is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Geron 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor IMMX or PRQR?

In the previous week, Immix Biopharma had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for ProQR Therapeutics. Immix Biopharma's average media sentiment score of 1.16 beat ProQR Therapeutics' score of 0.79 indicating that Immix Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immix Biopharma 2 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ProQR Therapeutics (PRQR) Competitors

$2.29 -0.03 (-1.29%)

As of 08/28/2026 04:00 PM Eastern

Compare

PRQR vs. WVE, CADL, SLDB, GERN, and IMMX

Should you buy ProQR Therapeutics stock or one of its competitors? ProQR Therapeutics's main competitors and comparable companies include WAVE Life Sciences (WVE), Candel Therapeutics (CADL), Solid Biosciences (SLDB), Geron (GERN), and Immix Biopharma (IMMX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does ProQR Therapeutics compare to WAVE Life Sciences?

ProQR Therapeutics (NASDAQ:PRQR) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, profitability, valuation, institutional ownership, risk, earnings, media sentiment and analyst recommendations.

ProQR Therapeutics has higher earnings, but lower revenue than WAVE Life Sciences. ProQR Therapeutics is trading at a lower price-to-earnings ratio than WAVE Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	13.41	-$47.73M	-$0.46	N/A
WAVE Life Sciences	$42.73M	23.24	-$204.38M	-$1.09	N/A

ProQR Therapeutics has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

ProQR Therapeutics has a net margin of -223.51% compared to WAVE Life Sciences' net margin of -309.73%. WAVE Life Sciences' return on equity of -50.36% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, ProQR Therapeutics had 3 more articles in the media than WAVE Life Sciences. MarketBeat recorded 4 mentions for ProQR Therapeutics and 1 mentions for WAVE Life Sciences. WAVE Life Sciences' average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.79 indicating that WAVE Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
ProQR Therapeutics	Positive
WAVE Life Sciences	Very Positive

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ProQR Therapeutics presently has a consensus target price of $7.50, suggesting a potential upside of 227.51%. WAVE Life Sciences has a consensus target price of $22.53, suggesting a potential upside of 347.01%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe WAVE Life Sciences is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

Summary

WAVE Life Sciences beats ProQR Therapeutics on 10 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Candel Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Candel Therapeutics (NASDAQ:CADL) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Candel Therapeutics has a beta of -0.51, indicating that its share price is 151% less volatile than the broader market.

ProQR Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 227.51%. Candel Therapeutics has a consensus price target of $19.29, indicating a potential upside of 47.56%. Given ProQR Therapeutics' higher probable upside, equities research analysts clearly believe ProQR Therapeutics is more favorable than Candel Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Candel Therapeutics	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64

In the previous week, Candel Therapeutics had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Candel Therapeutics and 4 mentions for ProQR Therapeutics. ProQR Therapeutics' average media sentiment score of 0.79 beat Candel Therapeutics' score of 0.63 indicating that ProQR Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Candel Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Candel Therapeutics has lower revenue, but higher earnings than ProQR Therapeutics. Candel Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	13.41	-$47.73M	-$0.46	N/A
Candel Therapeutics	N/A	N/A	-$38.18M	-$1.41	N/A

Candel Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. ProQR Therapeutics' return on equity of -73.83% beat Candel Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Candel Therapeutics	N/A	-76.98%	-48.50%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 14.3% of Candel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

ProQR Therapeutics beats Candel Therapeutics on 9 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Solid Biosciences?

ProQR Therapeutics (NASDAQ:PRQR) and Solid Biosciences (NASDAQ:SLDB) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, analyst recommendations, earnings, dividends and profitability.

ProQR Therapeutics has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	13.41	-$47.73M	-$0.46	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.91	N/A

Solid Biosciences has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Solid Biosciences' return on equity of -71.35% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Solid Biosciences	N/A	-71.35%	-60.58%

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Solid Biosciences had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Solid Biosciences and 4 mentions for ProQR Therapeutics. Solid Biosciences' average media sentiment score of 0.92 beat ProQR Therapeutics' score of 0.79 indicating that Solid Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics has a beta of 0.07, indicating that its stock price is 93% less volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.41, indicating that its stock price is 141% more volatile than the broader market.

ProQR Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 227.51%. Solid Biosciences has a consensus price target of $18.18, indicating a potential upside of 86.10%. Given ProQR Therapeutics' higher probable upside, analysts plainly believe ProQR Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83

Summary

Solid Biosciences beats ProQR Therapeutics on 8 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Geron?

ProQR Therapeutics (NASDAQ:PRQR) and Geron (NASDAQ:GERN) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, media sentiment, analyst recommendations, profitability, earnings, dividends and valuation.

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 73.7% of Geron shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 1.7% of Geron shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Geron had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Geron and 4 mentions for ProQR Therapeutics. Geron's average media sentiment score of 1.76 beat ProQR Therapeutics' score of 0.79 indicating that Geron is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Geron	4 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

ProQR Therapeutics has higher earnings, but lower revenue than Geron. Geron is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	13.41	-$47.73M	-$0.46	N/A
Geron	$183.88M	5.28	-$83.50M	-$0.11	N/A

ProQR Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 227.51%. Geron has a consensus price target of $4.00, indicating a potential upside of 164.90%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe ProQR Therapeutics is more favorable than Geron.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Geron	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Geron has a net margin of -34.17% compared to ProQR Therapeutics' net margin of -223.51%. Geron's return on equity of -24.48% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-223.51%	-73.83%	-35.14%
Geron	-34.17%	-24.48%	-10.30%

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, Geron has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market.

Summary

Geron beats ProQR Therapeutics on 9 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Immix Biopharma?

Immix Biopharma (NASDAQ:IMMX) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Immix Biopharma has higher earnings, but lower revenue than ProQR Therapeutics. Immix Biopharma is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immix Biopharma	N/A	N/A	-$29.44M	-$0.88	N/A
ProQR Therapeutics	$17.99M	13.41	-$47.73M	-$0.46	N/A

Immix Biopharma presently has a consensus price target of $21.29, indicating a potential upside of 52.70%. ProQR Therapeutics has a consensus price target of $7.50, indicating a potential upside of 227.51%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Immix Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immix Biopharma	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.78
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63

11.3% of Immix Biopharma shares are owned by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are owned by institutional investors. 30.3% of Immix Biopharma shares are owned by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Immix Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market.

Immix Biopharma has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -223.51%. Immix Biopharma's return on equity of -38.44% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immix Biopharma	N/A	-38.44%	-34.72%
ProQR Therapeutics	-223.51%	-73.83%	-35.14%

In the previous week, Immix Biopharma had 1 more articles in the media than ProQR Therapeutics. MarketBeat recorded 5 mentions for Immix Biopharma and 4 mentions for ProQR Therapeutics. Immix Biopharma's average media sentiment score of 1.16 beat ProQR Therapeutics' score of 0.79 indicating that Immix Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immix Biopharma	2 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Immix Biopharma beats ProQR Therapeutics on 10 of the 15 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$241.28M	$3.94B	$7.21B	$12.91B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-4.98	11.62	273.16	25.45
Price / Sales	13.41	1,315.05	614.81	86.98
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	2.60	16.53	12.98	6.14
Net Income	-$47.73M	-$22.80M	$3.48B	$348.86M
7 Day Performance	-2.14%	-0.31%	0.13%	-0.80%
1 Month Performance	28.65%	9.80%	7.08%	4.13%
1 Year Performance	1.78%	55.66%	24.67%	15.17%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	4.1079 of 5 stars	$2.29 -1.3%	$7.50 +227.5%	+1.8%	$241.28M	$17.99M	N/A	180	News Coverage
WVE WAVE Life Sciences	3.3964 of 5 stars	$5.25 +2.5%	$22.53 +329.1%	-47.5%	$1.01B	$42.73M	N/A	240	Positive News
CADL Candel Therapeutics	2.9249 of 5 stars	$13.60 +5.8%	$19.29 +41.8%	+125.7%	$984.03M	N/A	N/A	60
SLDB Solid Biosciences	2.3668 of 5 stars	$9.89 +8.0%	$17.40 +75.9%	+78.3%	$982.18M	N/A	N/A	100	News Coverage Analyst Forecast
GERN Geron	2.2532 of 5 stars	$1.55 +2.0%	$4.00 +158.1%	+7.9%	$976.56M	$183.88M	N/A	70	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. WVE, CADL, SLDB, GERN, and IMMX

How does ProQR Therapeutics compare to WAVE Life Sciences?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Summary

How does ProQR Therapeutics compare to Solid Biosciences?

Summary

How does ProQR Therapeutics compare to Geron?

Summary

How does ProQR Therapeutics compare to Immix Biopharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. WVE, CADL, SLDB, GERN, and IMMX

How does ProQR Therapeutics compare to WAVE Life Sciences?

Which has stronger earnings & valuation, PRQR or WVE?

Which has more volatility & risk, PRQR or WVE?

Is PRQR or WVE more profitable?

Does the media prefer PRQR or WVE?

Do insiders and institutionals have more ownership in PRQR or WVE?

Do analysts prefer PRQR or WVE?

Summary

How does ProQR Therapeutics compare to Candel Therapeutics?

Which has more volatility and risk, PRQR or CADL?

Do analysts prefer PRQR or CADL?

Does the media refer more to PRQR or CADL?

Which has preferable valuation & earnings, PRQR or CADL?

Is PRQR or CADL more profitable?

Do insiders & institutionals have more ownership in PRQR or CADL?

Summary

How does ProQR Therapeutics compare to Solid Biosciences?

Which has better valuation and earnings, PRQR or SLDB?

Is PRQR or SLDB more profitable?

Do institutionals & insiders have more ownership in PRQR or SLDB?

Does the media refer more to PRQR or SLDB?

Which has more volatility & risk, PRQR or SLDB?

Do analysts prefer PRQR or SLDB?

Summary

How does ProQR Therapeutics compare to Geron?

Do insiders and institutionals have more ownership in PRQR or GERN?

Does the media prefer PRQR or GERN?

Which has stronger valuation & earnings, PRQR or GERN?

Do analysts prefer PRQR or GERN?

Is PRQR or GERN more profitable?

Which has more risk & volatility, PRQR or GERN?

Summary

How does ProQR Therapeutics compare to Immix Biopharma?

Which has higher valuation and earnings, IMMX or PRQR?

Do analysts recommend IMMX or PRQR?

Do institutionals and insiders believe in IMMX or PRQR?

Which has more risk & volatility, IMMX or PRQR?

Is IMMX or PRQR more profitable?

Does the media favor IMMX or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools